High-Dose Chemotherapy Followed by ASCT Improves Survival Compared with Non-myeloablative Consolidation in Primary CNS Lymphoma By Ogkologos - August 20, 2026 112 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MATRix/IELSG43 study Source RELATED ARTICLESMORE FROM AUTHOR Two novel bispecific antibodies in combination with chemotherapy show efficacy in neuroendocrine carcinomas Sacituzumab tirumotecan plus pembrolizumab significantly prolongs progression-free survival in advanced non-small cell lung cancer Adding Abiraterone to ADT and Docetaxel Improves Survival in Metastatic Prostate Cancer MOST POPULAR Dealing With Fears March 24, 2021 31-Year-Old Woman Diagnosed with Breast Cancer Just 11 Days Before Her... June 21, 2021 EMA Recommends Extension of Indications for Osimertinib December 18, 2024 Embracing Bravery When You Have a Genetic Cancer Disease January 13, 2021 Load more HOT NEWS Drug Combination Shows Promise for Rhabdomyosarcoma, but Can It Get to... Foodie Fridays: An Ode to Summer Tomatoes New Research on Treating Hormone Receptor-Positive Breast Cancer From SABCS 2020 How and When to Wash Your Reusable Cloth Mask and When...
